Claritin/Singulair combo stumbles
Executive Summary
Phase III trials of a combination of the antihistamine Claritin and the asthma agent Singulair "did not demonstrate a statistically significant improvement in the treatment of seasonal allergic rhinitis compared to each product administered separately," Schering-Plough and Merck say. The firms will continue to evaluate the results and may conduct additional studies. The combo is under development via a joint venture formed in 2000 (1"The Pink Sheet" May 29, 2000, p. 22). Merck is conducting Phase III trials of Singulair monotherapy for allergic rhinitis...
You may also be interested in...
Singulair Advantage In Allergies Is Leukotriene-Blocking Action, Merck Says
Merck's Singulair AR novel mechanism of action allows the asthma drug to work across multiple allergic rhinitis symptoms, Human Health President-Americas David Anstice told investors
Merck/Schering Ezetimibe Deal Is Part Of Growing Ties Between Firms
Merck is edging away from its strict go-it-alone policy and sidling up a little closer to Schering-Plough in a series of deals - the most recent of which is a co-promotion agreement with Schering-Plough for the Phase III cholesterol absorption inhibitor ezetimibe.
New EU Filings
Obecabtagene autoleucel, Autolus Therapeutics’s investigational treatment for relapsed or refractory B cell precursor acute lymphoblastic leukemia, is among the latest products that have been filed for review by the European Medicines Agency for potential EU marketing approval.